|Bid||1,651.20 x 0|
|Ask||1,651.60 x 0|
|Day's range||1,628.80 - 1,652.40|
|52-week range||1,408.80 - 1,767.00|
|Beta (3Y monthly)||0.85|
|PE ratio (TTM)||18.60|
|Earnings date||30 Oct 2019|
|Forward dividend & yield||0.76 (4.63%)|
|1y target est||1,644.50|
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Paul Summers picks out three defensive stocks that should hold their own in the event of a Brexit-linked recession.
Kenya on Friday began adding a malaria vaccine to its routine immunization schedule for babies and toddlers, becoming the third African country to roll out the vaccine for a disease that threatens children across the continent. Malaria, which kills one child globally every two minutes, is the top killer of children under five in the east African country. The vaccine - the world's first against malaria - will be administered to children under two and could be crucial to efforts to combat the disease, health officials said.
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: “Children with severe eosinophilic asthma currently have limited treatment choices available to them.
The settlement could be valued at up to $12 billion, they said, which would make it the largest such settlement in U.S. pharmaceutical history. The following are some of the largest previous U.S. legal settlements involving the pharmaceutical industry. * Merck & Co $4.85 billion, 2007 - Three years after it pulled its widely used arthritis pain drug Vioxx from the market over safety concerns and following several product liability trials, Merck agreed to pay nearly $5 billion to settle most of the 60,000 lawsuits alleging that Vioxx caused heart attacks and strokes.
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.
A company with a high Quality Rank has strong cash-generation, consistent profits, high rates of return on investment, high margins and robust financial health8230;
London's FTSE 100 overcame early losses to close higher on Tuesday as hopes of imminent interest rate cuts from major central banks buoyed sentiment, while JD Sports jumped to an all-time high on upbeat results. The blue-chip index added 0.4%, with JD Sports gaining 8.8% after its gym clothing and premium-branded fashion helped it post higher profit and offset UK retail sector gloom. The FTSE 250 rose 0.3%, helped in part by a nearly 13% surge in Cairn Energy as strong half-year results led to a production target upgrade.
London's FTSE 100 fell on Monday as the pound ploughed ahead after unexpectedly robust economic data and as no-deal Brexit worries tempered, leaving internationally-focussed stocks in the dumps. The blue-chip index lost 0.6%, shedding earlier gains and lagging its European peers, due to steep falls in pharmaceutical shares AstraZeneca, GlaxoSmithKline , and consumer goods giant Unilever. The FTSE 250 index dipped 0.1%, though losses were limited thanks to a 10.4% surge in Intu Properties after the Times reported that private equity firm Orion Capital Managers was looking to buy the shopping centre operator.
Long-term investing in shares like GlaxoSmithKline plc (LON:GSK) requires preparation, patience and discipline to successfully cover the long distance ahead.
Shares in GlaxoSmithKline plc (LON:GSK) look tempting after their recent rally, but you should read this before you buy the stock.
London's FTSE 100 slipped on Thursday as a surge in sterling pushed exporter stocks lower, missing out on a global rally led by growing hopes of a resolution to the U.S.-China trade dispute. The FTSE 100 slid 0.6%, with multinationals including spirits company Diageo, pharma giants AstraZeneca and GlaxoSmithKline slipping about 3% as a strong pound meant the value of their U.S. earnings was lower. Stocks trading without dividend entitlement on the day such as BHP, Glencore and Micro Focus fell between 1.2%-3%, weighing heavily on the blue-chip index.
Growing worries about Britain crashing out of the European Union and a general election that could usher in a new government and major changes to UK Plc have steepened the discount for London-listed companies with exposure to the domestic economy. Shares in London-listed companies that make the bulk of their revenue in Britain have suffered since the June 2016 referendum on European Union membership.
Desperate times mean desperate investors reach for so-called safe havens. GlaxoSmithKline plc (LON:GSK) and Legal & General plc (LON:LGEN) may not be sexy but they are solid.
AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its main target in the final stage of another trial last year. The British drugmaker said anifrolumab under the TULIP 2 program helped patients with systemic lupus erythematosus, commonly known as SLE. The drug had failed to meet its main goal in the final stage of one of the two clinical trials under the TULIP program last year https://in.reuters.com/article/us-astrazeneca-anifrolumab/astrazeneca-lupus-drug-fails-to-meet-main-goal-in-study-idINKCN1LG0MM.
Prospects for AstraZeneca's respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition. AstraZeneca said the late-stage ETHOS trial of triple-drug therapy Breztri Aerosphere, formerly known as PT010, helped patients suffering from chronic obstructive pulmonary disease (COPD), in a challenge to Glaxosmithkline’s Trelegy Ellipta.
GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business. Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion last year and an agreement in February to pay up to 3.7 billion euros ($4.09 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.
Two doses of belantamab mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the white blood cells, GSK said on Friday. GSK sold its approved oncology drugs to Novartis in 2014, but has staged a comeback in cancer treatment with a deal to buy U.S. firm Tesaro for $5.1 billion (£4.2 billion) last year and an agreement in February to pay up to 3.7 billion euros (£3.3 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy.